Management of multiple sclerosis patients in central European countries: current needs and potential solutions

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F18%3A10377604" target="_blank" >RIV/00064165:_____/18:10377604 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/18:10377604

Result on the web

<a href="http://dx.doi.org/10.1177/1756286418759189" target="_blank" >http://dx.doi.org/10.1177/1756286418759189</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1177/1756286418759189" target="_blank" >10.1177/1756286418759189</a>

Result language

angličtina

Original language name

Management of multiple sclerosis patients in central European countries: current needs and potential solutions

Original language description

Multiple sclerosis (MS) experts in Europe are facing rapidly rising demands of excellence due to the increasing complexity of MS therapy and management. A central European expert board of MS experts met to identify needs and obstacles with respect to raising quality of MS care in central and Eastern European countries. There are substantial variations across countries regarding delivery of care and its cost structure, as well as access to treatment. To date, Eastern European countries are often less able to afford reimbursement of immunomodulatory agents than Western countries. Overall, approximately 40% of working-age patients are not working due to MS. Costs rise steeply with increasing disability; indirect costs constitute the bulk of the financial burden in patients with severe MS. Magnetic resonance imaging (MRI) assessment is meanwhile obligatory as the diagnostic interface in the management of MS patients. Recommended measures directed at improving quality of care include the collection of patient data in registries, enhanced education of healthcare professionals, implementation of national strategies aiming at reducing regional variation, optimization of approval processes, and removal of administrative barriers. Local partnerships with authorities such as those that represent the interests of employees can contribute to leverage the importance of epidemiological data. The need for education extends to (neuro) radiologists who are responsible for reporting MRI findings in expert quality. Dissemination of the Magnetic Resonance Imaging in MS (MAGNIMS) protocol would be an important step in this context. Also, clinical freedom of choice is rated as essential. Physicians should have access to a range of treatment options due to the complexity of disease. Guidelines such as the upcoming EAN-ECTRIMS clinical practice guideline also aim at providing a basis for argumentation in negotiations with national health authorities.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30103 - Neurosciences (including psychophysiology)

Project

<a href="/en/project/GA16-03322S" target="_blank" >GA16-03322S: Investigation of pathomechanisms responsible for speech and voice disorders in multiple sclerosis using new methods of objective acoustic analysis</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Therapeutic Advances in Neurological Disorders

ISSN

1756-2856

e-ISSN

—

Volume of the periodical

11

Issue of the periodical within the volume

February

Country of publishing house

GB - UNITED KINGDOM

Number of pages

12

Pages from-to

1-12

UT code for WoS article

000441220800001

EID of the result in the Scopus database

2-s2.0-85054862551